Former Zacks biotech analyst Napodano charged with fraud after settling with SEC on insider trading cases
Jason Napodano gained some widespread recognition in a certain group of biotech investors and Twitter mavens while he was the senior biotech analyst at Zacks Small Cap Research. But for around three years, while Napodano was providing coverage on a slate of micro cap biotechs, he and a pair of colleagues in the brokerage business also ran a penny ante insider trading ring, allegedly sharing information as they schemed up ways to make thousands of dollars off the penny stocks he covered.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.